Related Experiment Video
Updated: May 13, 2025
Cholesterol Efflux Assay
Published on: March 6, 2012
A Systematic Review of Apolipoprotein A-I Mimetic Peptides for Atherosclerosis Therapy via Activation of the Reverse
Aiman Asaduddin1, Farida Aisyah1, Dono Indarto2
1Faculty of Medicine, Universitas Sebelas Maret, Surakarta, Indonesia.
Insights
Apolipoprotein A-I mimetic peptides (ApoA-I MPs) show promise in reducing atherosclerosis by enhancing HDL metabolism and cholesterol efflux via the Reverse Cholesterol Transport (RCT) pathway in mouse models. Further research is needed for human therapeutic development.
Area of Science:
- Cardiovascular Research
- Pharmacology
- Biochemistry
Background:
- High-density lipoprotein (HDL) is a potential therapeutic target for atherosclerosis.
- The Reverse Cholesterol Transport (RCT) pathway is crucial for modulating HDL metabolism.
- Apolipoprotein A-I mimetic peptides (ApoA-I MPs) enhance HDL metabolism.
Purpose of the Study:
- To systematically review the efficacy of ApoA-I MPs in reducing atherosclerosis in mouse models.
- To investigate the role of the RCT mechanism in ApoA-I MP-mediated anti-atherosclerotic effects.
Main Methods:
- Systematic review of in vivo studies over the last ten years.
- Searches conducted in PubMed, SCOPUS, ProQuest, and Science Direct.
- Adherence to the Systematic Review Protocol for Animal Intervention Studies (SYRCLE).
Main Results:
- 16 articles with low risk of bias were included.
- 13 of 16 studies demonstrated significant reduction in atherosclerotic plaque by ApoA-I MPs.
- ApoA-I MPs regulate HDL metabolism, increase cholesterol efflux, and stimulate the RCT pathway.
Conclusions:
- ApoA-I MPs effectively reduce atherosclerotic plaque in mice via enhanced cholesterol efflux through the RCT pathway.
- The anti-atherosclerotic effects may vary based on peptide sequence and administration route.
- Further investigation is warranted to support ApoA-I MP development as a human therapy for atherosclerosis.
Background:
HDL has been identified a s a p otential n ew t reatment f or atherosclerosis. Targeting lipid metabolism via the Reverse Cholesterol Transport (RCT) pathway can improve HDL metabolism. Apolipoprotein A-I mimetic peptides (ApoA-I MPs) are able to increase HDL metabolism. Thus, this systematic review aimed to examine the potential effect o f A poA-I M Ps a gainst a therosclerosis i n mice models through the RCT mechanism.
Method:
This systematic review was conducted using previous in vivo studies published in four scientific databases over the last ten years (PubMed, SCOPUS, ProQuest, and Science Direct) and was based on the Systematic Review Protocol for Animal Intervention Studies (SYRCLE) protocol.
Results:
This study's primary outcome was a reduction in atherosclerotic plaque, where 16 articles were qualified for this study. Based on the risk of bias analysis, these articles had a low risk of bias. Most in vivo studies (13 of 16) showed that ApoA-I MPs significantly reduced atherosclerotic plaque formation. Generally, ApoA-I MPs played an important role in regulating HDL metabolism (HDL remodeling process, increased cholesterol efflux, and stimulated RC T pathway) and an ti-inflammatory agent. Apo A-I MPs may differ in their ability to reduce atherosclerotic plaque depending on the peptide sequence and administration route.
Conclusions:
ApoA-I MPs can reduce atherosclerotic plaque formation in mice by increasing cholesterol efflux vi a th e RC T pa thway. Fu rther in vestigation is re quired to su pport th e de velopment of ApoA-I MPs as a new therapy for atherosclerosis in humans.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...